• Innovative Eye Science

    Your vision is our focus

    Play
    Select Video
  • Play
    Select Video
  • Play
    Select Video
  • Play
    Select Video

At Inotek, we're working to define the future of glaucoma treatment.

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.

Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.

A New Class of Glaucoma Therapy

Our most advanced product candidate, trabodenoson, is a highly selective adenosine mimetic and the first potential treatment for glaucoma of its kind.

Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.

Read More >

News

Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma

- Trial Did Not Achieve Superiority to Placebo at All 12 Time Points- - Diurnal IOP Reduction of 4.25mmHg at Three Months with Trabodenoson 6% Once-a-day Dose, Statistically Superior to Placebo - - Safety and Tolerability Similar to Placebo- - Conference Call Scheduled for 8:30am EST Today - LEXINGTON, Mass.--(BUSINESS WIRE)--Jan. 3,...

Read More >